A phase II study of intermittent Gleevec (imatinib mesylate) and weekly paclitaxel in patients aged 70 or older with advanced non-small cell lung cancer.

Trial Profile

A phase II study of intermittent Gleevec (imatinib mesylate) and weekly paclitaxel in patients aged 70 or older with advanced non-small cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2015

At a glance

  • Drugs Imatinib (Primary) ; Paclitaxel (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jul 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 24 Jul 2012 Status changed from `active, no longer recruiting' to `discontinued' as reported by ClinicalTrials.gov.
    • 20 Oct 2011 Planned End Date changed from 1 Aug 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov (NCT01011075).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top